【Successful Development of Pathology AI】Now Possible for Highly Accurate Detection of Prostate Cancer -Published in Cancers / Special Issue: Artificial Intelligence in Oncology–
Medmain Inc., a provider of the digital pathology support solutions “PidPort”, has successfully developed a pathological AI that enables to classify a prostate cancer with high accuracy in digital histopathology of transurethral resection specimens by using deep learning and transfer learning.
We are also pleased to announce that a paper on this development has been posted on Cancers, issued by MDPI (https://www.mdpi.com), and published in a special issue of Artificial Intelligence in Oncology on September 28, 2022.
https://www.mdpi.com/2072-6694/14/19/4744
*This achievement was made possible by a grant from the New Energy and Industrial Technology Development Organization (NEDO).
Tweet